# A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

> **NCT06259526** · PHASE2 · COMPLETED · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 267 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Placebo group
- **DRUG:** JS1-1-01 low-dose group
- **DRUG:** JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules
- **DRUG:** JS1-1-01 high-dose group
- **DRUG:** Active drug group

## Key facts

- **NCT ID:** NCT06259526
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-26
- **Primary completion:** 2024-10-23
- **Final completion:** 2024-10-23
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06259526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06259526, "A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06259526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*